FDA approves new combination therapy for multiple myeloma

The U.S. Food and Drug Administration (FDA) has granted accelerated approval to Zenbexus (iberdomide) in combination with daratumumab and dexamethasone for adults with relapsed or refractory multiple myeloma. This decision provides a new treatment option for patients whose cancer has returned or stopped responding to previous therapies, based on trial results showing improved response rates.